4th Quarter - Report

APOTEX CORP. for APOTEX CORP.

Firm
Client
Income
—
Expenses
$90,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

S. 1882, The Fair and Immediate Release of Generics Act S. 27, The Preserve Access to Affordable Pharmaceuticals Act Actelion Pharmaceutical LTD and Actelion Clinical Research Inc. V. Apotex Inc., Apotex Corp., and Roxane Laboratories Inc. The use of Risk Evaluation and Mitigation Strategies (REMS) by brand drug companies to delay generic competition Establishment of a federal track and trace system for pharmaceuticals Adoption of an electronic labeling system for pharmaceuticals

Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Shermfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1882 (112th), S. 27 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.